Why the study?
Does omapatrilat improve ischaemic wall thickening and exercise capacity in a canine model of exercise-induced myocardial dysfunction compared to vehicle, fosinoprilat, or nitroglycerin?
Population
Chronically instrumented dogs with exercise-induced myocardial dysfunction induced by progressive closure of…
Comparison
Omapatrilat (0.3 mg/kg) vs Vehicle, fosinoprilat, and nitroglycerin
Design
Preclinical
Follow-up
4 hours
Authors
Loading...
Supports vasopeptidase inhibition for ischaemic dysfunction in animals; hypothesis-generating and should not change practice.
Does omapatrilat improve ischaemic wall thickening and exercise capacity in a canine model of exercise-induced myocardial dysfunction compared to vehicle, fosinoprilat, or nitroglycerin?
In a canine model of exercise-induced myocardial dysfunction, acute vasopeptidase inhibition with omapatrilat improved ischaemic function and exercise capacity comparably to nitroglycerin.
Holzgrefe et al. (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: